I 
117TH CONGRESS 
1ST SESSION H. R. 2344 
To require the use of prescription drug monitoring programs. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 1, 2021 
Mr. RYAN (for himself and Mr. BALDERSON) introduced the following bill; 
which was referred to the Committee on Energy and Commerce 
A BILL 
To require the use of prescription drug monitoring programs. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Prescription Drug 
Monitoring Act of 2021’’. 
SEC. 2. REQUIRING THE USE OF PRESCRIPTION DRUG 
MONITORING PROGRAMS. 
(a) DEFINITIONS.—In this section: 
(1) 
CONTROLLED
SUBSTANCE.—The 
term 
‘‘controlled substance’’ has the meaning given the 
term in section 102 of the Controlled Substances 
Act (21 U.S.C. 802). 
VerDate Sep 11 2014 
01:49 May 26, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2344.IH
H2344
pbinns on DSKJLVW7X2PROD with BILLS
(2) COVERED
STATE.—The term ‘‘covered 
State’’ means a State that receives funding under 
the Harold Rogers Prescription Drug Monitoring 
Program established under the Departments of 
Commerce, Justice, and State, the Judiciary, and 
Related Agencies Appropriations Act, 2002 (Public 
Law 107–77; 115 Stat. 748), or under the con-
trolled substance monitoring program under section 
399O of the Public Health Service Act (42 U.S.C. 
280g–3). 
(3) DISPENSER.—The term ‘‘dispenser’’— 
(A) means a person licensed or otherwise 
authorized by a State to deliver a prescription 
drug product to a patient or an agent of the pa-
tient; and 
(B) does not include a person involved in 
oversight or payment for prescription drugs. 
(4) PDMP.—The term ‘‘PDMP’’ means a pre-
scription drug monitoring program. 
(5) PRACTITIONER.—The term ‘‘practitioner’’ 
means a practitioner registered under section 303(f) 
of the Controlled Substances Act (21 U.S.C. 823(f)) 
to prescribe, administer, or dispense controlled sub-
stances. 
VerDate Sep 11 2014 
01:49 May 26, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2344.IH
H2344
pbinns on DSKJLVW7X2PROD with BILLS
(6) STATE.—The term ‘‘State’’ means each of 
the several States and the District of Columbia. 
(b) REQUIREMENTS.—Beginning 1 year after the 
date of enactment of this Act, each covered State shall 
require— 
(1) each prescribing practitioner within the cov-
ered State or their designee, who shall be licensed or 
registered healthcare professionals or other employ-
ees who report directly to the practitioner, to consult 
the PDMP of the covered State before initiating 
treatment with a prescription for a controlled sub-
stance listed in schedule II, III, or IV of section 
202(c) of the Controlled Substances Act (21 U.S.C. 
812(c)), and every 3 months thereafter as long as 
the treatment continues; 
(2) the PDMP of the covered State to provide 
proactive notification to a practitioner when patterns 
indicative of controlled substance misuse, including 
opioid misuse, are detected; 
(3) each dispenser within the covered State to 
report each prescription for a controlled substance 
dispensed by the dispenser to the PDMP not later 
than 24 hours after the controlled substance is dis-
pensed to the patient; 
VerDate Sep 11 2014 
01:49 May 26, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2344.IH
H2344
pbinns on DSKJLVW7X2PROD with BILLS
(4) that the PDMP make available a quarterly 
de-identified data set and an annual report for pub-
lic and private use, including use by healthcare pro-
viders, health plans and health benefits administra-
tors, State agencies, and researchers, which shall, at 
a minimum, meet requirements established by the 
Attorney General, in coordination with the Secretary 
of Health and Human Services; 
(5) each State agency that administers the 
PDMP to— 
(A) proactively analyze data available 
through the PDMP; and 
(B) provide reports to law enforcement 
agencies and prescriber licensing boards de-
scribing any prescribing practitioner that re-
peatedly fall outside of expected norms or 
standard practices for the prescribing practi-
tioner’s field; and 
(6) that the data contained in the PDMP of the 
covered State be made available to other States. 
(c) NONCOMPLIANCE.—If a covered State fails to 
comply with subsection (a), the Attorney General or the 
Secretary of Health and Human Services may withhold 
grant funds from being awarded to the covered State 
under the Harold Rogers Prescription Drug Monitoring 
VerDate Sep 11 2014 
01:49 May 26, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2344.IH
H2344
pbinns on DSKJLVW7X2PROD with BILLS
Program established under the Departments of Com-
merce, Justice, and State, the Judiciary, and Related 
Agencies Appropriations Act, 2002 (Public Law 107–77; 
115 Stat. 748), or under the controlled substance moni-
toring program under section 399O of the Public Health 
Service Act (42 U.S.C. 280g–3). 
Æ 
VerDate Sep 11 2014 
01:49 May 26, 2021
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H2344.IH
H2344
pbinns on DSKJLVW7X2PROD with BILLS